Researchers and executives are gearing up for the annual meeting of the American Association for Cancer Research (AACR), which will be held in Philadelphia from April 18 - 22, where it's safe to say immuno-oncology will continue to rule the roost. Beyond the big data presentations of checkpoint inhibitors and CAR T cells themselves, among the most urgent question is how to help more patients realize the promise of immuno-oncology.